NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

特發性多中心性淋巴结增生症(iMCD):流行病學洞察(2030年前的預測)

idiopathic Multicentric Castleman's disease (iMCD) - Epidemiology Insight - 2030

出版商 DelveInsight Business Research LLP 商品編碼 966787
出版日期 按訂單生產 內容資訊 英文 100 Pages
商品交期: 10個工作天內
價格
特發性多中心性淋巴结增生症(iMCD):流行病學洞察(2030年前的預測) idiopathic Multicentric Castleman's disease (iMCD) - Epidemiology Insight - 2030
出版日期: 按訂單生產內容資訊: 英文 100 Pages
簡介

本報告提供世界主要7個國家(美國,歐洲5個國家(德國,法國,義大利,西班牙,英國),日本)的特發性多中心性淋巴结增生症(iMCD)的相關調查,提供流行病學及預測,各市場區隔的病例,診斷案例等資訊。

目錄

第1章 主要洞察

第2章 摘要整理

第3章 疾病的背景和概要

  • 概要
  • 徵兆與症狀
  • 病理學
  • 危險因素
  • 診斷

第4章 患者的治療過程

第5章 流行病學和患者人口

  • 流行病學的主要調查結果
  • 前提條件與理論的根據:主要7個國家
  • 流行病學方案:主要7個國家
    • 流行病學方案(2017-2030)
  • 美國流行病學
  • 各流行病學歐洲5個國家
    • 德國流行病學
    • 法國流行病學
    • 義大利流行病學
    • 西班牙流行病學
    • 英國流行病學
  • 日本流行病學

第6章 治療流程,目前治療,及醫務

  • 治療和管理
  • 治療流程

第7章 KOL的見解

第8章 未滿足需求

第9章 附錄

  • 參考文獻
  • 報告的調查手法

第10章 DelveInsight的服務內容

第11章 免責聲明

第12章 關於DelveInsight

目錄
Product Code: DIEI1062

DelveInsight's 'idiopathic Multicentric Castleman's disease (iMCD) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted idiopathic Multicentric Castleman's disease (iMCD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

idiopathic Multicentric Castleman's disease (iMCD) Understanding

The DelveInsight idiopathic Multicentric Castleman's disease (iMCD) epidemiology report gives a thorough understanding of the idiopathic Multicentric Castleman's disease (iMCD) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for idiopathic Multicentric Castleman's disease (iMCD) in the US, Europe, and Japan. The report covers the detailed information of the idiopathic Multicentric Castleman's disease (iMCD) epidemiology scenario in seven major countries (US, EU5, and Japan).

idiopathic Multicentric Castleman's disease (iMCD) Epidemiology Perspective by DelveInsight

The idiopathic Multicentric Castleman's disease (iMCD) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The idiopathic Multicentric Castleman's disease (iMCD) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The idiopathic Multicentric Castleman's disease (iMCD) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

idiopathic Multicentric Castleman's disease (iMCD) Detailed Epidemiology Segmentation

The idiopathic Multicentric Castleman's disease (iMCD) epidemiology covered in the report provides historical as well as forecasted idiopathic Multicentric Castleman's disease (iMCD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight idiopathic Multicentric Castleman's disease (iMCD) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The idiopathic Multicentric Castleman's disease (iMCD) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The idiopathic Multicentric Castleman's disease (iMCD) Epidemiology Report and Model provide an overview of the risk factors and global trends of idiopathic Multicentric Castleman's disease (iMCD) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of idiopathic Multicentric Castleman's disease (iMCD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of idiopathic Multicentric Castleman's disease (iMCD)
  • The report provides the segmentation of the idiopathic Multicentric Castleman's disease (iMCD) epidemiology

Report Highlights:

  • 11-Year Forecast of idiopathic Multicentric Castleman's disease (iMCD) epidemiology
  • 7MM Coverage
  • Total Cases of idiopathic Multicentric Castleman's disease (iMCD)
  • Total Cases of idiopathic Multicentric Castleman's disease (iMCD) according to segmentation
  • Diagnosed cases of idiopathic Multicentric Castleman's disease (iMCD)

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to idiopathic Multicentric Castleman's disease (iMCD)?
  • What are the key findings pertaining to the idiopathic Multicentric Castleman's disease (iMCD) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of idiopathic Multicentric Castleman's disease (iMCD) across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the idiopathic Multicentric Castleman's disease (iMCD)?
  • What are the currently available treatments of idiopathic Multicentric Castleman's disease (iMCD)?

Reasons to buy:

  • The idiopathic Multicentric Castleman's disease (iMCD) Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global idiopathic Multicentric Castleman's disease (iMCD) market
  • Quantify patient populations in the global idiopathic Multicentric Castleman's disease (iMCD) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for idiopathic Multicentric Castleman's disease (iMCD) therapeutics in each of the markets covered
  • Understand the magnitude of idiopathic Multicentric Castleman's disease (iMCD) population by its epidemiology
  • The idiopathic Multicentric Castleman's disease (iMCD) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of idiopathic Multicentric Castleman's disease (iMCD)

3. idiopathic Multicentric Castleman's disease (iMCD) : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. idiopathic Multicentric Castleman's disease (iMCD) Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. idiopathic Multicentric Castleman's disease (iMCD) Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. idiopathic Multicentric Castleman's disease (iMCD) Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. idiopathic Multicentric Castleman's disease (iMCD) Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. idiopathic Multicentric Castleman's disease (iMCD) Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. idiopathic Multicentric Castleman's disease (iMCD) Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. idiopathic Multicentric Castleman's disease (iMCD) Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. idiopathic Multicentric Castleman's disease (iMCD) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. idiopathic Multicentric Castleman's disease (iMCD) Treatment and Management
  • 6.2. idiopathic Multicentric Castleman's disease (iMCD) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

List of Tables

  • Table 1: idiopathic Multicentric Castleman's disease (iMCD) Epidemiology in 7MM (2017-2030)
  • Table 2: idiopathic Multicentric Castleman's disease (iMCD) Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: idiopathic Multicentric Castleman's disease (iMCD) Epidemiology in the United States (2017-2030)
  • Table 4: idiopathic Multicentric Castleman's disease (iMCD) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: idiopathic Multicentric Castleman's disease (iMCD) Epidemiology in Germany (2017-2030)
  • Table 6: idiopathic Multicentric Castleman's disease (iMCD) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: idiopathic Multicentric Castleman's disease (iMCD) Epidemiology in France (2017-2030)
  • Table 8: idiopathic Multicentric Castleman's disease (iMCD) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: idiopathic Multicentric Castleman's disease (iMCD) Epidemiology in Italy (2017-2030)
  • Table 10: idiopathic Multicentric Castleman's disease (iMCD) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: idiopathic Multicentric Castleman's disease (iMCD) Epidemiology in Spain (2017-2030)
  • Table 12: idiopathic Multicentric Castleman's disease (iMCD) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: idiopathic Multicentric Castleman's disease (iMCD) Epidemiology in the United Kingdom (2017-2030)
  • Table 14: idiopathic Multicentric Castleman's disease (iMCD) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: idiopathic Multicentric Castleman's disease (iMCD) Epidemiology in Japan (2017-2030)
  • Table 16: idiopathic Multicentric Castleman's disease (iMCD) Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: idiopathic Multicentric Castleman's disease (iMCD) Epidemiology in 7MM (2017-2030)
  • Figure 2: idiopathic Multicentric Castleman's disease (iMCD) Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: idiopathic Multicentric Castleman's disease (iMCD) Epidemiology in the United States (2017-2030)
  • Figure 4: idiopathic Multicentric Castleman's disease (iMCD) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: idiopathic Multicentric Castleman's disease (iMCD) Epidemiology in Germany (2017-2030)
  • Figure 6: idiopathic Multicentric Castleman's disease (iMCD) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: idiopathic Multicentric Castleman's disease (iMCD) Epidemiology in France (2017-2030)
  • Figure 8: idiopathic Multicentric Castleman's disease (iMCD) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: idiopathic Multicentric Castleman's disease (iMCD) Epidemiology in Italy (2017-2030)
  • Figure 10: idiopathic Multicentric Castleman's disease (iMCD) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: idiopathic Multicentric Castleman's disease (iMCD) Epidemiology in Spain (2017-2030)
  • Figure 12: idiopathic Multicentric Castleman's disease (iMCD) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: idiopathic Multicentric Castleman's disease (iMCD) Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: idiopathic Multicentric Castleman's disease (iMCD) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: idiopathic Multicentric Castleman's disease (iMCD) Epidemiology in Japan (2017-2030)
  • Figure 16: idiopathic Multicentric Castleman's disease (iMCD) Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report